knowledge -WSS

knowledge

author：fashion 2025-10-01 11:35:13 - browse：42463

Enticed by the immense market opened by GLP-1 weight loss drugs Wegovy and Zepbound, a handful of biotech companies are trying to develop next-generation, longer-lasting therapies based on a very different approach: RNA interference.

This Nobel Prize-winning science works by degrading the biological blueprints that RNA use to make proteins — without the genetic instructions, the troublesome proteins are never made and the gene is essentially muted.

If the companies succeed, it would be a significant shift in the obesity treatment revolution, away from weekly drugs targeting hormones to medications that could be given much less frequently — twice a year or even less — and pinpoint genetic contributors to weight.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： What could happen if Russia blows up the Zaporizhzhia Nuclear Power Plant?

focus

leisure time

WSS

Crowdfunding for medical bills sidesteps core problem, author says

Neutralizing antibodies against HIV shows promise in children

Novel spinal cord stimulator treats paralysis without surgery

Empower primary care with adequate payments and technology

FDA approves Leqembi, a milestone in Alzheimer’s treatment

Most antidepressants don't work on kids, teens, study finds

focus

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Moonlake's readout produced a cash windfall. Risks remain

How a small hospital in rural Puerto Rico survived Hurricane Maria

Drug repurposing or repositioning? The language matters

Sen. Bill Cassidy on how to lower drug prices

After affirmative action ruling, medical educators look to 'holistic review'

Crowdfunding for medical bills sidesteps core problem, author says

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

With fresh data, a dynamic duo powers Eli Lilly to new heights

Medical leaders decry Supreme Court decision on affirmative action

The effects of a landmark ruling on DNA ownership are becoming clearer

entertainment

Titanic submersible: What a 'catastrophic implosion' means and what officials found

Brain technologies pose threats that are all too real, experts warn

PBM executives asked to testify by House panel

Sen. Bill Cassidy on how to lower drug prices

Neutralizing antibodies against HIV shows promise in children

PBM executives asked to testify by House panel

focus

focus

leisure time

Wikipedia